WallStreetZenWallStreetZen

NASDAQ: BIIB
Biogen Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Biogen earnings were $1.6B for the trailing 12 months ending Sep 30, 2025, with -1.1% growth year over year. The latest BIIB earnings report on Sep 30, 2025 announced Q3 2025 earnings of $466.5M, down 26.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BIIB reported annual earnings of $1.6B, with 40.6% growth. The next BIIB earnings date is Jan 29, 2026.

BIIB past earnings growth

How has BIIB's earnings growth performed historically?

Company
-1.08%
Industry
367.26%
Market
55.02%
BIIB's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
BIIB's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
BIIB's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

BIIB earnings history

Current Revenue
$10.1B
Current Earnings
$1.6B
Current Profit Margin
16%
BIIB's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

BIIB Return on Equity

Current Company
9.3%
Current Industry
118.3%
Current Market
35.1%
BIIB's Return on Equity (9.3%)... subscribe to Premium to read more.
High Return on Equity Performance

BIIB Return on Assets

Current Company
5.7%
Current Industry
11.9%
BIIB is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when BIIB announces earnings.

BIIB Return on Capital Employed

Current Company
7.35%
Current Industry
19.9%
BIIB's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

BIIB vs General Drug Manufacturer Stocks

TickerEBITDAEarningsY/Y EarningsEPS
BIIB$2.71B$1.61B-18.34%$10.99
GRFS$1.71B$174.36M-25.16%$0.26
OGN$1.56B$501.00M-24.63%$1.93
AMRN-$80.28M-$86.19MN/A-$4.20
SCLX-$319.06M-$375.84MN/A-$31.85
View Top General Drug Manufacturer Stocks

BIIB earnings dates

Next earnings date
Jan 29, 2026

Biogen Earnings Reports & History FAQ

What were Biogen's earnings last quarter?

On BIIB's earnings call on Invalid Date, Biogen (NASDAQ: BIIB) reported Q3 2025 earnings per share (EPS) of $3.18, up 19.1% year over year. Total BIIB earnings for the quarter were $466.50 million. In the same quarter last year, Biogen's earnings per share (EPS) was $2.67.

If you're new to stock investing, here's how to buy Biogen stock.

When does Biogen report earnings?

The next BIIB earnings call is Invalid Date. Add BIIB to your watchlist to be reminded of Biogen's next earnings date.

Is Biogen profitable or losing money?

As of the last Biogen earnings report, Biogen is currently profitable. Biogen's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $1.61 billion, a 0.41% decrease year over year.

What was BIIB's earnings growth in the past year?

As of Biogen's earnings date in Invalid Date, Biogen's earnings has grown -1.08% year over year. This is 368.34 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 367.26%. BIIB earnings in the past year totalled $1.61 billion.

What are Biogen's earnings expectations?

The current EPS estimate for Biogen's earnings report in Invalid Date is $1.76.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.